ວັນອັງຄານ, ໄດ້ FDA ໄດ້ອະນຸມັດການເລັ່ງລັດ ສໍາລັບການ ImmunoGen Inc’s (NASDAQ: IMGN) Elahere (mirvetuximab soravtansine-gynx) for folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
HC Wainwright says the approved label does not require a prior treatment with bevacizumab, which according to management, could nearly double the eligible patient population.
The analyst increased the price target from $12 to $20, with a Buy rating.
Elahere’s broader-than-expected label might result from the FDA’s access to preliminary objective response rate (ORR) and duration of response (DOR) data from both arms of the MIRASOL study.
Elahere’s label includes a boxed warning for ocular toxicities, but HC Wainwright believes it would have a limited impact on Elahere’s adoption.
Each 21-day cycle treatment would cost $18,000-$25,000, with an annual cost of $182,400 per patient.
ຕະຫຼາດ BMO Capital says ImmunoGen shares were under pressure (-13% vs. -0.26% XBI) following the Elahere approval conference call, which was a surprise.
BMO analyst raised the price target from $17 to $19 on incrementally more positive on MIRASOL data in early 2023.
The analyst expects mirvetuximab can only achieve ~$300 million peak sales, undervaluing the ovarian cancer opportunity.
ລາຄາປະຕິບັດງານ: IMGN shares are up 5.09% at $5.27 on the last check Wednesday.
Latest Ratings for IMGN
ວັນທີ່ສະຫມັກ | ບໍລິສັດ | ການປະຕິບັດ | From | To |
|---|---|---|---|---|
Feb 2022  | SVB Leerink | ຮັກສາ | ປະຕິບັດການຕະຫຼາດ | |
Feb 2022 | BMO ນະຄອນຫຼວງ | ລິເລີ່ມການຄຸ້ມຄອງໃນ | ເກັ່ງກວ່າ | |
Dec 2021 | Jefferies | ການຍົກລະດັບ | ຖື | ຊື້ |
View More Analyst Ratings for IMGN
ເບິ່ງເພີ່ມເຕີມຈາກ Benzinga
ຢ່າພາດການແຈ້ງເຕືອນແບບສົດໆໃນຫຸ້ນຂອງເຈົ້າ – ເຂົ້າຮ່ວມ Benzinga Pro ສໍາລັບການຟຣີ! ລອງໃຊ້ເຄື່ອງມືທີ່ຈະຊ່ວຍໃຫ້ທ່ານລົງທຶນຢ່າງສະຫຼາດຂຶ້ນ, ໄວຂຶ້ນ, ແລະດີກວ່າ.
©ປີ 2022 Benzinga.com. Benzinga ບໍ່ໃຫ້ ຄຳ ແນະ ນຳ ດ້ານການລົງທືນ. ທິການ.
Source: https://finance.yahoo.com/news/fda-approval-ovarian-cancer-drug-192106962.html